Literature DB >> 12161031

Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis.

T Kuhlmann1, M Glas, C zum Bruch, W Mueller, A Weber, F Zipp, W Brück.   

Abstract

Clinical course, outcome, radiological features, severity, and histopathology are heterogenous in multiple sclerosis (MS). Since MS is considered to be a polygenic disease, the genetic background may at least partly be responsible for this variability. Some MS cases are histopathologically characterized by a dramatic oligodendrocyte loss that is in part caused by apoptosis. A dysregulated apoptotic elimination of self-reactive T cells may also contribute to disease susceptibility. To analyze genetic differences in the apoptosis regulating factors bcl-2, bax, bcl-x and p53 we investigated polymorphisms of these genes in 105 patients with a relapsing remitting disease course and 99 controls by PCR-SSCP and direct sequencing. We identified so far unpublished sequence alterations in the promotor region of the bxl-x gene, in exon 7 of the p53 gene, and in exon 1 of the bax gene. No differences were observed between MS patients and controls. Additional known polymorphisms were found in intron 3 of the bax gene and in exon 6 of the p53 gene. No significant differences in the frequency of gene sequence variations were found between MS patients and controls. The apoptosis genes studied here therefore appear less likely to be important effector genes in MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161031     DOI: 10.1016/s0165-5728(02)00167-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

1.  Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination.

Authors:  Jiadong Li; Cristina A Ghiani; Jin Young Kim; Aixiao Liu; Juan Sandoval; Jean DeVellis; Patrizia Casaccia-Bonnefil
Journal:  J Neurosci       Date:  2008-06-11       Impact factor: 6.167

2.  Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage.

Authors:  Richard T Libby; Yan Li; Olga V Savinova; Joseph Barter; Richard S Smith; Robert W Nickells; Simon W M John
Journal:  PLoS Genet       Date:  2005-07-25       Impact factor: 5.917

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.